Indication

In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

Medicine details

Medicine name:
olaparib (Lynparza)
SMC ID:
SMC2617
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
11 March 2024
SMC meeting date:
06 February 2024
Patient group submission deadline:
TBC